Immuno-Biological Laboratories Co.,Ltd. [4570.T]
TOKYO, May 12 (Pulse News Wire) – Immuno-biological Laboratories CO.,LTD. (4570.T) announced today that its board approved changes in leadership roles contingent upon shareholder approval at the upcoming extraordinary general meeting scheduled for June 25, 2026.
The proposed changes include the appointment of Shigeo Nakayama as Executive Director and Chief Operating Officer, Yoshihiro Okazumi as a permanent audit committee member, and Koichi Kojima as another independent audit committee member. Additionally, three external directors—Kojiro Oshima, Masaharu Okuzumi, and Eisaku Tajima—are set to step down effective at the conclusion of the shareholders' meeting.
In preparation for transitioning to an audit committee firm, the company also confirmed the retirement of two existing external directors, Kojiro Oshima and Masaharu Okuzumi, who will take up new positions within the audit committee structure. Further details on the amendments to the company's articles of incorporation related to this transition were disclosed separately in a notice released today.
🟡 Confidence: Standard AI-translated content.